PPARalpha deficiency in inflammatory cells suppresses tumor growth.

Inflammation in the tumor bed can either promote or inhibit tumor growth. Peroxisome proliferator-activated receptor (PPAR)alpha is a central transcriptional suppressor of inflammation, and may therefore modulate tumor growth. Here we show that PPARalpha deficiency in the host leads to overt inflamm...

Full description

Bibliographic Details
Main Authors: Arja Kaipainen, Mark W Kieran, Sui Huang, Catherine Butterfield, Diane Bielenberg, Gustavo Mostoslavsky, Richard Mulligan, Judah Folkman, Dipak Panigrahy
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2007-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC1800345?pdf=render
id doaj-e7bf0ded47594b8e8efa923304c5d5e5
record_format Article
spelling doaj-e7bf0ded47594b8e8efa923304c5d5e52020-11-25T01:57:35ZengPublic Library of Science (PLoS)PLoS ONE1932-62032007-01-0122e26010.1371/journal.pone.0000260PPARalpha deficiency in inflammatory cells suppresses tumor growth.Arja KaipainenMark W KieranSui HuangCatherine ButterfieldDiane BielenbergGustavo MostoslavskyRichard MulliganJudah FolkmanDipak PanigrahyInflammation in the tumor bed can either promote or inhibit tumor growth. Peroxisome proliferator-activated receptor (PPAR)alpha is a central transcriptional suppressor of inflammation, and may therefore modulate tumor growth. Here we show that PPARalpha deficiency in the host leads to overt inflammation that suppresses angiogenesis via excess production of the endogenous angiogenesis inhibitor thrombospondin-1 and prevents tumor growth. Bone marrow transplantation and granulocyte depletion show that PPARalpha expressing granulocytes are necessary for tumor growth. Neutralization of thrombospondin-1 restores tumor growth in PPARalpha-deficient mice. These findings suggest that the absence of PPARalpha activity renders inflammatory infiltrates tumor suppressive and, thus, may provide a target for inhibiting tumor growth by modulating stromal processes, such as angiogenesis.http://europepmc.org/articles/PMC1800345?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Arja Kaipainen
Mark W Kieran
Sui Huang
Catherine Butterfield
Diane Bielenberg
Gustavo Mostoslavsky
Richard Mulligan
Judah Folkman
Dipak Panigrahy
spellingShingle Arja Kaipainen
Mark W Kieran
Sui Huang
Catherine Butterfield
Diane Bielenberg
Gustavo Mostoslavsky
Richard Mulligan
Judah Folkman
Dipak Panigrahy
PPARalpha deficiency in inflammatory cells suppresses tumor growth.
PLoS ONE
author_facet Arja Kaipainen
Mark W Kieran
Sui Huang
Catherine Butterfield
Diane Bielenberg
Gustavo Mostoslavsky
Richard Mulligan
Judah Folkman
Dipak Panigrahy
author_sort Arja Kaipainen
title PPARalpha deficiency in inflammatory cells suppresses tumor growth.
title_short PPARalpha deficiency in inflammatory cells suppresses tumor growth.
title_full PPARalpha deficiency in inflammatory cells suppresses tumor growth.
title_fullStr PPARalpha deficiency in inflammatory cells suppresses tumor growth.
title_full_unstemmed PPARalpha deficiency in inflammatory cells suppresses tumor growth.
title_sort pparalpha deficiency in inflammatory cells suppresses tumor growth.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2007-01-01
description Inflammation in the tumor bed can either promote or inhibit tumor growth. Peroxisome proliferator-activated receptor (PPAR)alpha is a central transcriptional suppressor of inflammation, and may therefore modulate tumor growth. Here we show that PPARalpha deficiency in the host leads to overt inflammation that suppresses angiogenesis via excess production of the endogenous angiogenesis inhibitor thrombospondin-1 and prevents tumor growth. Bone marrow transplantation and granulocyte depletion show that PPARalpha expressing granulocytes are necessary for tumor growth. Neutralization of thrombospondin-1 restores tumor growth in PPARalpha-deficient mice. These findings suggest that the absence of PPARalpha activity renders inflammatory infiltrates tumor suppressive and, thus, may provide a target for inhibiting tumor growth by modulating stromal processes, such as angiogenesis.
url http://europepmc.org/articles/PMC1800345?pdf=render
work_keys_str_mv AT arjakaipainen pparalphadeficiencyininflammatorycellssuppressestumorgrowth
AT markwkieran pparalphadeficiencyininflammatorycellssuppressestumorgrowth
AT suihuang pparalphadeficiencyininflammatorycellssuppressestumorgrowth
AT catherinebutterfield pparalphadeficiencyininflammatorycellssuppressestumorgrowth
AT dianebielenberg pparalphadeficiencyininflammatorycellssuppressestumorgrowth
AT gustavomostoslavsky pparalphadeficiencyininflammatorycellssuppressestumorgrowth
AT richardmulligan pparalphadeficiencyininflammatorycellssuppressestumorgrowth
AT judahfolkman pparalphadeficiencyininflammatorycellssuppressestumorgrowth
AT dipakpanigrahy pparalphadeficiencyininflammatorycellssuppressestumorgrowth
_version_ 1724973961572253696